Cannabinoid Hyperemesis Syndrome |
| Cannabis
has long occupied an unusual position in medicine and culture. For
centuries it has been associated with relief—of pain, anxiety,
nausea, and loss of appetite. In modern clinical practice, cannabinoids
are frequently invoked as antiemetics, particularly in
chemotherapy-induced nausea and vomiting. Yet over the past two
decades, an unsettling paradox has emerged: in a subset of chronic
users, cannabis appears to provoke the very symptoms it is known to
suppress. Cannabinoid Hyperemesis Syndrome (CHS) is the name given to
this contradiction, and its increasing prevalence reflects both
changing patterns of cannabis use and the evolving potency of the
substance itself. CHS is characterized by recurrent episodes of severe nausea, vomiting, and abdominal pain in the setting of chronic cannabis exposure. Patients are often young, otherwise healthy, and deeply familiar with emergency departments long before a diagnosis is made. What distinguishes CHS from other causes of cyclic vomiting is not a laboratory test or imaging finding, but a constellation of behaviors, histories, and responses that only become coherent when cannabis use is examined honestly and longitudinally. The syndrome often unfolds in phases. In the prodromal period, patients experience early-morning nausea, vague epigastric discomfort, and a growing fear of vomiting. Appetite may decline, but cannabis use frequently increases, driven by the belief that it will alleviate symptoms. This phase can persist for months or years, often unnoticed or misattributed to anxiety, gastritis, or functional gastrointestinal disorders. Over time, however, the illness progresses into a hyperemetic phase marked by relentless vomiting, abdominal pain, dehydration, electrolyte disturbances, and repeated hospital visits. Vomiting may occur dozens of times per day, leading to acute kidney injury, metabolic derangements, and profound physical exhaustion. One of the most striking features of CHS is the compulsive use of hot showers or baths for symptomatic relief. Patients often describe standing under scalding water for prolonged periods, sometimes multiple times a day, as the only intervention that provides even transient comfort. This behavior is so characteristic that its presence strongly supports the diagnosis, yet it is frequently overlooked or dismissed as incidental. The relief appears to be mediated through cutaneous heat activation rather than psychological comfort, suggesting a neurophysiologic mechanism rather than a learned coping strategy. The pathophysiology of CHS remains incompletely understood, but several converging mechanisms have been proposed. Chronic exposure to delta-9-tetrahydrocannabinol (THC) appears to alter cannabinoid receptor signaling, particularly at the CB1 receptor, which plays a central role in gastrointestinal motility, visceral sensation, and emesis control. With sustained stimulation, these receptors may become dysregulated or desensitized, leading to a paradoxical proemetic effect. THC also interacts with dopamine and serotonin pathways, both of which are intimately involved in nausea and vomiting. Over time, these interactions may shift from inhibitory to excitatory, especially in susceptible individuals. Another important pathway involves the transient receptor potential vanilloid 1 (TRPV1) receptor, commonly known as the capsaicin receptor. TRPV1 is activated by heat and capsaicin and plays a role in pain perception and autonomic regulation. Chronic cannabis use appears to overstimulate TRPV1 receptors centrally while impairing their peripheral modulation, leading to splanchnic vasodilation, nausea, and abdominal pain. External heat or topical capsaicin may temporarily restore balance by activating peripheral TRPV1 receptors, explaining both the compulsive hot bathing behavior and the emerging role of capsaicin cream as a therapeutic adjunct. Clinically, CHS presents a diagnostic challenge because it closely resembles cyclic vomiting syndrome (CVS), a disorder of gut–brain interaction that predates the recognition of CHS by more than a century. Both conditions feature episodic vomiting with symptom-free intervals, abdominal pain, and significant morbidity. The key distinction lies in the temporal relationship between cannabis use and symptom onset, as well as the resolution of symptoms with sustained abstinence. Unfortunately, this distinction is often blurred because patients with CVS may use cannabis to self-medicate, and patients with CHS frequently deny or underreport use, either due to stigma or genuine disbelief that cannabis could be the cause. Laboratory and imaging studies in CHS are typically nonspecific. Mild leukocytosis, hypokalemia, metabolic alkalosis, and elevated creatinine from dehydration are common but not diagnostic. Imaging studies are often normal and rarely change management, yet they are frequently repeated as clinicians search for structural explanations. The absence of definitive tests contributes to diagnostic delay and unnecessary healthcare utilization, reinforcing patient frustration and clinician uncertainty. Acute management of CHS focuses on supportive care. Intravenous fluids are essential to correct dehydration and electrolyte abnormalities. Traditional antiemetics such as ondansetron or promethazine may provide partial relief but are often ineffective. Dopamine antagonists, particularly those that act centrally, have demonstrated greater efficacy in controlling symptoms, though they require careful monitoring due to potential cardiac and extrapyramidal side effects. Benzodiazepines may be helpful in select cases, especially when anxiety exacerbates symptoms, but they do not address the underlying mechanism. Topical capsaicin applied to the abdomen has emerged as a low-cost, low-risk intervention that can reduce nausea and vomiting by exploiting TRPV1-mediated pathways. Despite these measures, the only definitive treatment for CHS is complete cessation of cannabis use. Symptom resolution typically occurs within days to weeks of abstinence, though residual nausea may persist as THC is slowly released from adipose tissue. Relapse is common if cannabis use resumes, often with a shorter latency and more severe symptoms. This pattern underscores the importance of recognizing CHS not only as a gastrointestinal disorder but also as a condition intertwined with substance use behavior, mental health, and social context. The chronic phase of management therefore extends beyond the emergency department or hospital ward. Patients require education that reframes cannabis not as a remedy but as a trigger. This conversation is often difficult, particularly in an era when cannabis is widely perceived as benign or therapeutic. Many patients express disbelief, anger, or grief when confronted with the diagnosis, especially if cannabis has played a central role in their identity, coping strategies, or social environment. Addressing comorbid anxiety, depression, and substance use disorder is critical to sustained recovery, as these conditions frequently drive continued use despite clear consequences. CHS is not a benign syndrome. Repeated episodes of severe vomiting can lead to esophageal injury, aspiration, acute renal failure, and life-threatening electrolyte disturbances. Prolonged QT intervals, particularly in the context of antiemetic use, increase the risk of malignant arrhythmias. The economic burden is substantial, driven by repeated emergency visits, hospitalizations, diagnostic testing, and lost productivity. Yet despite its growing prevalence, CHS remains underrecognized, underdiagnosed, and often misunderstood. The increasing legalization and commercialization of cannabis have altered both the frequency and intensity of exposure. Modern cannabis products often contain significantly higher concentrations of THC than those used in prior decades, and new delivery systems allow for rapid, repeated dosing. These changes may partially explain why CHS is being identified more frequently and at younger ages. At the same time, cultural narratives surrounding cannabis as a natural or harmless substance may delay recognition of its adverse effects, both by patients and clinicians. Understanding CHS requires abandoning simple binaries of "good" or "bad" drugs and embracing a more nuanced view of dose, duration, individual susceptibility, and neurobiology. Cannabis can be both antiemetic and emetogenic, therapeutic and toxic, depending on context. CHS occupies the uncomfortable space where these contradictions converge, reminding clinicians that physiology does not always conform to expectation or intention. As awareness grows, earlier recognition of CHS offers the possibility of reducing harm, avoiding unnecessary testing, and guiding patients toward effective treatment. Doing so requires careful listening, nonjudgmental inquiry into substance use, and a willingness to question assumptions—both the patient's and the clinician's. In this sense, CHS is not only a medical syndrome but also a lesson in clinical humility: a reminder that even familiar remedies can betray us when used without limits, and that relief, like illness, often carries a history we must learn to read. References: 1- Lonsdale H, Wilsey MJ: Paediatric cannabinoid hyperemesis. Current Opinion in Pediatrics. 34(5):510–515, 2022 2- Geraci E, Cake C, Mulieri KM, Fenn NE 3rd: Comparison of antiemetics in the management of pediatric cannabinoid hyperemesis syndrome. Journal of Pediatric Pharmacology and Therapeutics. 28(3):222–227, 2023 3- Shah M, Jergel A, George RP, Jenkins E, Bashaw H: Distinguishing clinical features of cannabinoid hyperemesis syndrome and cyclic vomiting syndrome: A retrospective cohort study. The Journal of Pediatrics. 271:114054, 2024 4- Ibia IE, Toce MS: Cannabis hyperemesis syndrome in children: A review of epidemiology, pathology, diagnosis, and treatment. Pediatric Emergency Care. 41(5):397–405, 2025 5- Meyer J, Burns MM: Current recommendations in the diagnosis and management of cannabinoid hyperemesis syndrome. Current Opinion in Pediatrics. 37(3):240–243, 2025 6- Yacob D: Cyclic vomiting syndrome and cannabinoid hyperemesis syndrome: Their intersection and joint existence. Gastroenterology Clinics of North America. 54(3):557–568, 2025 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|